Serum Institute of India (SII) Pune on Tuesday said it is currently working to develop a vaccine for Mpox with positive outcomes expected in a year’s time
Vaccine major SII on Friday announced to acquire 20 per cent stake in medical device company IntegriMedical to advance in needle-free injection system technology
Covishield is the Indian variant of AstraZeneca's Covid-19 vaccine. AstraZeneca recently admitted that its vaccine can cause a rare side-effect called ‘TTS.’